Hjem › Blodkreft › New York › New York City
Kliniske studier for Blodkreft i New York City, NY
26 studier for Blodkreft søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekruttererFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RekruttererFase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
RekruttererFase 1
- NYU Langone Health, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- Mount Sinai Medical Center, New York
Genomic Profiling in Cancer Patients
RekruttererObservasjonsstudie
- Metropolitan Hospital Center, New York
- Ralph Lauren Center for Cancer Care and Prevention, New York
- Memorial Sloan Kettering Cancer Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruttererFase 3
- David H. Koch Center for Cancer Care, New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RekruttererFase 1/2
- Research Site, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
RekruttererFrivillige helsepersonell ønskes velkommen
- NYP/Weill Cornell Medical Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruttererFase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- og 3 flere
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RekruttererFase 2
- New York University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
IVIG for Infection Prevention After CAR-T-Cell Therapy
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center, New York
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RekruttererFase 3
- New York Presbyterian Hospital, New York
- Mt Sinai Medical Center, New York
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
RekruttererObservasjonsstudie
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RekruttererFrivillige helsepersonell ønskes velkommen
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruttererFase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RekruttererObservasjonsstudie
- Memorial Sloan Kettering Cancer Center, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekruttererFase 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RekruttererFase 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Blodkreft-studier i andre byer
- Houston, TX46 studier
- Boston, MA25 studier
- Washington, DC19 studier
- Seattle, WA18 studier
- Baltimore, MD18 studier
- Los Angeles, CA17 studier
- Durham, NC16 studier
- Chicago, IL15 studier
- Philadelphia, PA14 studier
- Columbus, OH13 studier
- Edison, NJ13 studier
- Nashville, TN13 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.